06/17/2024
https://www.congress.gov...
"I would say those discussions were pretty significant."
"I want to get to the real crux of the problem here, because I think we are confusing the approval rate versus the ability of a patient like Matt to actually get a drug and have the 'Right to Try.'"
"Members of Congress beat up on the FDA, and so, they become even more risk averse."
"The cost. Companies develop drugs because, in the end, they are reporting to shareholders and they have to make a profit."